Shares of The Bristol-Myers Squibb Company (NYSE: BMY)are attempting to claw their way back into positive territory after the sharp post-earnings sell-off. The company beat on the top and bottom lines. However, the biopharmaceutical giant’s cautious 2025 guidance had some investors heading for the exits. In midday trading, BMY stock isdown approximately 2%. However, the stock was down about 3.8% at the market open.
Early stock price movement is generally dictated by high-speed trading programs that are designed to move first and analyze second. The fact that BMY stock is off its lows and that it was a favorite of analysts before the earnings report suggests taking a minute to figure out what the earnings report showed and what it may mean for the stock.
